FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to a pharmaceutical composition inhibiting an apoptosis protein comprising, as an active ingredient, a crystalline hemihydrate form HA (S)-N-((S)-1-cyclohexyl-2-{(S)-2-[4-(4-fluorobenzoyl)thiazol-2-yl]pyrrolidine-1-yl}-2-oxoethyl)-2-methylaminopropionamide characterized by the formula (I), in an amount of more than 100 mg and pharmaceutically acceptable excipients. Crystalline hemihydrate form HA of compound (I) is characterized by a powder X-ray diffraction pattern comprising three or more values of 2θ, selected from the group consisting of 8.3 ± 0.2, 9.5 ± 0.2, 13.5 ± 0.2, 17.3 ± 0.2, 18.5 ± 0.2 and 18.9 ± 0.2 at room temperature. Composition of the invention further comprises a surfactant, an acid, an antioxidant.
(I).
EFFECT: technical result is an oral pharmaceutical composition with a high content of active agent.
24 cl, 18 dwg, 17 ex, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SOLID ORAL FORMULATIONS AND CRYSTALLINE FORMS OF APOPTOSIS PROTEIN INHIBITOR | 2010 |
|
RU2574405C2 |
| COMBINATION OF IAP AND FLT3 INHIBITORS | 2007 |
|
RU2456983C2 |
| CRYSTALLINE FORMS OF THE TLR7/TLR8 INHIBITOR | 2019 |
|
RU2792005C2 |
| NOVEL CRYSTALLINE FORMS OF SODIUM SALT OF (4-{4-[5-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLAMINO)PYRIDIN-2-YL]PHENYL}CYCLOHEXYL) ACETIC ACID | 2011 |
|
RU2612556C2 |
| CRYSTALLINE FORMS OF LTA4H INHIBITOR | 2019 |
|
RU2808992C2 |
| SALT OF PYRROLIDIN-3-YL-ACETIC ACID DERIVATIVE AND ITS CRYSTALS | 2014 |
|
RU2640047C2 |
| CRYSTAL FORM OF PHOSPHODIESTERASE INHIBITOR, METHOD OF ITS PREPARATION AND USE | 2020 |
|
RU2814498C2 |
| 3-[2-(DIMETHYLAMINO)METHYL-(CYCLOHEX-1-YL)]PHENOL MALEATE AND ITS CRYSTALLINE FORMS | 2006 |
|
RU2434845C2 |
| SALTS AND CRYSTALLINE FORMS | 2014 |
|
RU2654855C2 |
| INDAZOLE DERIVATIVE SALTS AND THEIR CRYSTALS | 2017 |
|
RU2747399C2 |
